<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37689093</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-0183</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Autoimmunity reviews</Title><ISOAbbreviation>Autoimmun Rev</ISOAbbreviation></Journal><ArticleTitle>Severity of neurological Long-COVID symptoms correlates with increased level of autoantibodies targeting vasoregulatory and autonomic nervous system receptors.</ArticleTitle><Pagination><StartPage>103445</StartPage><MedlinePgn>103445</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.autrev.2023.103445</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1568-9972(23)00179-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Long-COVID syndrome constitutes a plethora of persisting symptoms with neurological disorders being the most disabling ones. The pathogenesis of Long-COVID is currently under heavy scrutiny and existing data on the role of auto-immune reaction to G-protein coupled receptors (GPCR) are conflicting.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This monocentric, cross-sectional study included patients who suffered a mild to moderate SARS-CoV-2 infection up to 12&#xa0;months prior to enrollment with (n&#xa0;=&#xa0;72) or without (n&#xa0;=&#xa0;58) Long-COVID diagnosis according to the German S1 guideline or with no known history of SARS-CoV-2 infection (n&#xa0;=&#xa0;70). While autoantibodies specific for the vasoregulation associated Adrenergic Receptor (ADR) B1 and B2 and the CNS and vasoregulation associated muscarinic acetylcholine receptor (CHR) M3 and M4 were measured by ELISA, neurological disorders were quantified by internationally standardized questionnaires.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The prevalence and concentrations of evaluated autoantibodes were significantly higher in Long-COVID compared to the 2 other groups (p&#xa0;=&#xa0;2.1*10<sup>-9</sup>) with a significantly higher number of patients with simultaneous detection of more than one autoantibody in the Long-COVID group (p&#xa0;=&#xa0;0.0419). Importantly, the overall inflammatory state was low in all 3 groups. ARB1 and ARB2 correlated negatively CERAD Trail Marking A and B (R&#xa0;&#x2264; -0.26, p&#xa0;&#x2264; 0.043), while CHRM3 correlated positively with Chadler Fatigue Scale (R&#xa0;=&#xa0;0.37, p&#xa0;=&#xa0;0.0087).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Concentrations of autoantibodies correlates to the intensity of neurological disorders including psychomotor speed, visual search, attention, and fatigue.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seibert</LastName><ForeName>Felix S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Medical Department 1, Marien Hospital Herne - Universit&#xe4;tsklinikum der Ruhr-Universit&#xe4;t Bochum, H&#xf6;lkeskampring 40, 44625 Herne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stervbo</LastName><ForeName>Ulrik</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Center for Translational Medicine, Marien Hospital Herne - Universit&#xe4;tsklinikum der Ruhr-Universit&#xe4;t Bochum, H&#xf6;lkeskampring 40, 44625 Herne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiemers</LastName><ForeName>Lea</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical Department 1, Marien Hospital Herne - Universit&#xe4;tsklinikum der Ruhr-Universit&#xe4;t Bochum, H&#xf6;lkeskampring 40, 44625 Herne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skrzypczyk</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Translational Medicine, Marien Hospital Herne - Universit&#xe4;tsklinikum der Ruhr-Universit&#xe4;t Bochum, H&#xf6;lkeskampring 40, 44625 Herne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hogeweg</LastName><ForeName>Maximillian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Department 1, Marien Hospital Herne - Universit&#xe4;tsklinikum der Ruhr-Universit&#xe4;t Bochum, H&#xf6;lkeskampring 40, 44625 Herne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertram</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Department 1, Marien Hospital Herne - Universit&#xe4;tsklinikum der Ruhr-Universit&#xe4;t Bochum, H&#xf6;lkeskampring 40, 44625 Herne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurek</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Translational Medicine, Marien Hospital Herne - Universit&#xe4;tsklinikum der Ruhr-Universit&#xe4;t Bochum, H&#xf6;lkeskampring 40, 44625 Herne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anft</LastName><ForeName>Moritz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Translational Medicine, Marien Hospital Herne - Universit&#xe4;tsklinikum der Ruhr-Universit&#xe4;t Bochum, H&#xf6;lkeskampring 40, 44625 Herne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westhoff</LastName><ForeName>Timm H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Medical Department 1, Marien Hospital Herne - Universit&#xe4;tsklinikum der Ruhr-Universit&#xe4;t Bochum, H&#xf6;lkeskampring 40, 44625 Herne, Germany. Electronic address: timm.westhoff@elisabethgruppe.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babel</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Translational Medicine, Marien Hospital Herne - Universit&#xe4;tsklinikum der Ruhr-Universit&#xe4;t Bochum, H&#xf6;lkeskampring 40, 44625 Herne, Germany; Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, and Berlin Institute of Health, Center for Regenerative Therapies, Augustenburger Platz 1, 13353 Berlin, Germany. Electronic address: nina.babel@elisabethgruppe.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Autoimmun Rev</MedlineTA><NlmUniqueID>101128967</NlmUniqueID><ISSNLinking>1568-9972</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000595896">CHRM3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043587">Receptor, Muscarinic M3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001341" MajorTopicYN="N">Autonomic Nervous System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="Y">Nervous System Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043587" MajorTopicYN="N">Receptor, Muscarinic M3</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiadrenergic</Keyword><Keyword MajorTopicYN="N">Anticholinergic</Keyword><Keyword MajorTopicYN="N">Antimuscarinergic</Keyword><Keyword MajorTopicYN="N">Autoantibodies</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Chronic fatigue</Keyword><Keyword MajorTopicYN="N">Coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">Post-COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>10</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>9</Day><Hour>19</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37689093</ArticleId><ArticleId IdType="doi">10.1016/j.autrev.2023.103445</ArticleId><ArticleId IdType="pii">S1568-9972(23)00179-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>